Market Report Source

Overview

The cardiovascular therapeutic area has historically provided the largest single source of revenue for the pharmaceutical industry. The outlook for the market remains robust, driven by high patient populations and a widespread focus on preventative treatment. However, low growth rates in established indications will prevail due to the growing availability of effective generic medicines and an overall scarcity of innovative new drug launches. With product launches in mainstream cardiovascular indications facing continued difficulties, major pharma companies are now primarily focusing efforts upon compliance and protection against the generic threats posed by line extensions and combination treatments. Changes in the competitive positions of leading companies will become inevitable as new revenue sources continue to decline and established portfolios underperform.

The Cardiovascular Market Outlook to 2012 is a new report published by Business Insights that provides comprehensive coverage of every class of drugs across all major cardiovascular indications. Detailed insights into recent key events and future market leaders are also provided, in addition to epidemiological analysis and forecasts for major products over the period 2007-12. With coverage of over 90% of the total market for cardiovascular products, this report profiles the underlying trends and factors driving the market and identifies the most promising areas of potential growth. Discover the key market trends and growth drivers of the cardiovascular market, assess the competitive dynamics of leading companies and evaluate the future prospects of major products with this new report.

Some Key Findings from this Report:

• Zetia, Diovan, Crestor and Lipitor were the strongest performing major products of 2006-07. Each of these brands is forecast to maintain patent protection over the short to medium-term.
• The cardiovascular portfolios of Novartis and AstraZeneca are best positioned for high levels of future growth. Conversely, it is forecast that current market leaders Pfizer,Merck and Sanofi-Aventis will struggle to preserve their market shares over the 2008-12 period.
• The cardiac therapy area is the only segment forecast to experience a decline in net sales during the forecast period. However, generic competition to Lipitor may also result in the Dyslipidemia market suffering a fall in sales over 2011-12.
• Thrombosis will be the major growth driver of the cardiovascular area throughout the short-term, whilst heart failure has the most favourable dynamics of any indication for rapid market growth.
• Heart failure and thrombosis represent the most active areas of current drug development. Increasing competition in these traditionally less competitive therapeutic areas is forecast to become a major trend over the period up to 2012.

Key Issues Examined in this Report:

• Cardiac therapies. Heart failure treatments have become a focal point for cardiovascular drug developments. However, doubts remain over whether the marginal benefits offered by such medicines will be sufficient to generate and sustain high levels of revenue.
• Combination drugs. Although combination drugs failed to accrue strong sales growth in 2007, the growing acceptance of combination dyslipidemic therapies amongst payors and physicians will favour Merck’s Vytorin/Inegy and Novartis’ newly launched combination product Exforge (amlodipine/losartan)
• Empty pipelines. Currently marketed portfolios have taken on greater importance in light of weak late stage pipelines among players such as Merck, BMS and AstraZeneca. This lack of new revenue sources is forecast to depress future growth in the cardiovascular market.
• Market leaders. Few leading companies are expected to retain their presence in the cardiovascular market, with some major players set to experience drastic declines in revenue over the forecast period.

Your Questions Answered:

• Which indications will experience the greatest growth in the global cardiovascular market over the period 2007-12?
• How will generic competition influence the future of branded products and which defensive strategies provide the most effective protection?
• How have recent major product launches performed?
• What is the forecast market size and growth rate over the period 2007-2012 across the major cardiovascular indications?
• Which pipeline products offer the highest growth potential?
• What will be the competitive landscape of hypertension, thrombosis, dyslipidemia and arrhythmia in 2012?

Top Five Reasons to Order Your Copy Today:

• Assess patient potential, treatment trends and sales patterns across major cardiovascular indications with this report’s analysis of epidemiological studies, unmet medical need, and economic imperatives for stakeholders.
• Measure the market performance and strategic positioning of major pharmaceutical corporations with this report’s evaluation of the franchises and market shares of AstraZeneca, BMS, Daiichi Sankyo, GSK, Merck, Novartis, Pfizer, Sanofi-Aventis and Servier.
• Discover the market dynamics of the cardiovascular area and understand the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting R&D.
• Compare the future prospects of key players and forecast sales of leading products across major indications to 2012 with this report’s analysis of sales focus by drug class, currently marketed portfolios, R&D pipelines, and trends in promotional spend for key brands.
• Identify the strategies that offer the greatest success potential within the future cardiovascular market and understand the challenges currently facing companies within this therapeutic area.

Table of Contents

Executive Summary
Patient potential
Global market analysis
Pipeline analysis
Competitive landscape
Chapter 1 Epidemiology of Cardiovascular
disorders
Summary
Introduction
Cardiovascular Risk Factors
Hypertension
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Dyslipidemia
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Diabetes
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Cardiovascular disease
Overview
Epidemiology
Acute thrombotic events
Acute coronary syndromes
Venous thromboembolism
Stroke
Cardiovascular procedures

Chapter 2 Global market analysis
Summary
Introduction
Market analysis by country
Licensing trends
Market analysis by drug class
Leading brands dynamics
Key events in the cardiovascular market
Use of ACE inhibitors by pregnant women linked to associated birth defects
risks
Arrival of generic competition to key brands
Positive clinical trials further boost sales generation for major brands Diovan
and Lipitor
Anti-hypertensives
Market analysis by drug class
Leading brands in the Anti-hypertensives market
ACE Inhibitors (ACEIs)
Market dynamics
Key brands analysis
Beta Blockers
Market dynamics
Diuretics
Market dynamics
Key brands analysis
Calcium Channel Blockers (CCBs)
Market dynamics
Key brands analysis
Angiotensin Receptor Blockers (ARBs)
Market dynamics
Key brands analysis
Sales forecasts to 2012 for Anti Hypertensives
Anti-dyslipidemics
Market analysis by drug class
Leading brands in the Anti-dyslipidemics market
Market analysis by drug class
Statins
Fibrates
Non-statin products
Other anti-dyslipidemics
Sales forecasts to 2012 for Anti dyslipidemics
Anti-Thrombotics
Market analysis by drug class
Leading brand dynamics
Anti-platelets
Market dynamics
Key brands analysis
Heparins
Market dynamics
Key brands analysis
Vit K antagonists
Fibrinolytics
Sales forecasts to 2012 for Anti thrombotics
Cardiac Therapies
Market analysis by drug class
Leading brands of Cardiac Therapies
Other cardiac therapies
Nitrites and nitrates
Leading-brand dynamics
Anti-arrhythmics
Sales forecasts to 2012 for Cardiac Therapies 2007-12
Total CVD market sales forecasts to 2012

Chapter 3 Pipeline analysis
Summary
Introduction
Key trends in cardiovascular R&D
Combination drugs
New class of drugs
New mechanism of action
New drug delivery formulations
The pipeline for cardiovascular disorders
Leading drugs in development
Profiles of key pipeline products
Phase II compounds
ARC 1779
KB 2115
Phase III compounds
Cleviprex (clevidipine)
Stedicor (azimilide)
BAY-597939 (rivaroxaban)
Drugs pending approval
Thelin (sitaxsentan)
Simcor (niacin and simvastatin)
Recently marketed drugs
Azor (amlodipine/olmesartan)
Tekturna/Rasilez (aliskiren)
Exforge (amlodipine/valsartan)
Ranexa (ranolazine)

Chapter 4 Competitive landscape
Summary
Company market shares
Pfizer
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Merck
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Novartis
Overview
Sales focus by drug class
Marketed product portfolio
R&D compounds
Strategic and growth analysis
Drivers of growth
Resistors of growth
Sanofi Aventis
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
AstraZeneca
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Bristol-Myers Squibb
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Daiichi Sankyo
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Servier
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Glaxo SmithKline
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth

Chapter 5 Appendix
ATC codes used in analysis
Licensing status as per IMS Health
Original brand
Other brand
Licensed brand
Not-coded product
Unbranded/ generic product
Diagnosis profile analysis
Index

List of Figures
Figure 1.1: Relationship between Cardiovascular Risk Factors and Diseases
Figure 1.2: Typical treatment patterns in the treatment of hypertension
Figure 1.3: Typical treatment patterns in the treatment of dyslipidemia
Figure 1.4: Typical treatment patterns in the treatment of diabetes
Figure 1.5: Typical treatment patterns in the treatment of acute thrombotic events
Figure 2.6: Global cardiovascular market share by geography, 2007
Figure 2.7: Sales of types of cardiovascular brands, 2006-07
Figure 2.8: Competitive dynamics of the global CVD market by drug class, 2007
Figure 2.9: Forecast dynamics of the leading 10 cardiovascular brands, 2006-07
Figure 2.10: Competitive dynamics in the global anti-hypertensives market by drug class, 2006–07
Figure 2.11: Market movement for anti-hypertensive brands, 2006
Figure 2.12: Diagnosis profile of ACE inhibitor sales, 2006
Figure 2.13: Diagnosis profile of Beta Blockers, 2006
Figure 2.14: Diagnosis profile of Calcium channel blockers, 2006
Figure 2.15: Diagnosis profile of ARBs, 2006
Figure 2.16: Diagnosis profile of Anti-dyslipidemics, 2006
Figure 2.17: Competitive dynamics in the global anti-thrombotics market by class, 2006–07
Figure 2.18: Market movement for anti-thrombotic brands, 2006
Figure 2.19: Diagnosis profile of anti-platelets, 2006
Figure 2.20: Diagnosis profile of Heparins, 2006
Figure 2.21: Diagnosis profile of cardiac therapies, 2006
Figure 2.22: Competitive dynamics in the global cardiac therapies market by class, 2006–07
Figure 3.23: Prevailing R&D approaches for cardiovascular diseases, 2006
Figure 3.24: The CVD pipeline by indication and stage of development, 2006
Figure 3.25: Leading recently launched and late-stage cardiovascular products, 2007
Figure 4.26: Competitive dynamics of the leading players in the global cardiovascular market, 2007
Figure 4.27: Pfizer’s franchise sales by drug class, 2006
Figure 4.28: Merck’s franchise sales by drug class, 2006
Figure 4.29: Novartis’ franchise sales by drug class, 2006
Figure 4.30: Sanofi Aventis’ franchise sales by drug class, 2006
Figure 4.31: AstraZeneca’s franchise sales by drug class, 2006
Figure 4.32: BMS’ franchise sales by drug class, 2006
Figure 4.33: Daiichi’s franchise sales by drug class, 2006
Figure 4.34: Servier’s franchise sales by drug class, 2006
Figure 4.35: GSK’s franchise sales by drug class, 2006

List of Tables
Table 1.1: Estimated prevalence of CVD across the seven major pharmaceutical markets, 2006
Table 1.2: Proposed revision definition of hypertension, 2005
Table 1.3: Estimated prevalence of hypertension in across seven major markets, 2006
Table 1.4: Forecast epidemiology of hypertension across the seven major markets, 2006-12
Table 1.5: Clinical guidelines for adult patients at borderline and high risk of cardiovascular disease by serum levels of lipids
Table 1.6: Estimated prevalence of dyslipidemia across seven major markets, 2006
Table 1.7: Forecast epidemiology of dyslipidemia across the seven major markets, 2006-12
Table 1.8: Various pharmacological therapies for the treatment and management of diabetes
Table 1.9: Estimated prevalence of diabetes in the seven major markets, 2006
Table 1.10: Forecast epidemiology of diabetes across the seven major markets, 2006-12
Table 1.11: Estimated prevalence of major cardiovascular diseases in the seven major markets, 2006
Table 1.12: Estimated incidence of ACS in the seven major markets, 2006
Table 1.13: Estimated incidence of VTE in the seven major markets, 2006
Table 1.14: Prevalence of stroke in the seven major markets, 2006
Table 1.15: Estimated incidence of cardiovascular procedures in the seven major markets, 2006
Table 2.16: Breakdown of the global CVD market by drug class, 2003-07
Table 2.17: Leading brands in the global cardiovascular market, 2006–07
Table 2.18: Breakdown of the global anti-hypertensive market by drug class, 2003-07
Table 2.19: Leading anti-hypertensive brands, 2006–07
Table 2.20: Leading ACE inhibitor brands, 2006–07
Table 2.21: Leading Beta blocker brands, 2006–07
Table 2.22: Leading diuretics brands, 2006–07
Table 2.23: Leading CCBs brands in the global CVD market, 2006–07
Table 2.24: Leading ARBs brands in the global CVD market, 2006–07
Table 2.25: Anti-hypertensives sales forecast for ARBs, Beta-blockers & CCBs, 2007-12
Table 2.26: Anti-hypertensives sales forecast for ACE inhibitors, Diuretics & Pipeline products, 2007-12
Table 2.27: Breakdown of the global anti-dyslipidemic market by drug class, 2003-07
Table 2.28: Leading anti-dyslipidemia products in the global CVD market, 2006–07
Table 2.29: Anti-dyslipidemics sales forecasts, 2007-12
Table 2.30: Breakdown of the global anti-thrombotics market by drug class, 2003-07
Table 2.31: Leading anti-thrombotics products in the global CVD market, 2006–07
Table 2.32: Leading anti-platelet brands in the global CVD market, 2006–07
Table 2.33: Leading heparin brands in the global CVD market, 2006–07
Table 2.34: Anti-thrombotics sales forecasts, 2007-12
Table 2.35: Breakdown of the global anti-thrombotics market by drug class, 2003-07
Table 2.36: Leading cardiac therapy products in the global CVD market, 2006–07
Table 2.37: Cardiac therapies’ sales forecasts, 2007-12
Table 2.38: Cardiovacular market sales forecasts by drug class, 2006-12 ($m)
Table 4.39: Leading players in the global cardiovascular disorders market, 2006-07
Table 4.40: Pfizer’s CVD product portfolio, 2005-06
Table 4.41: Pfizer’s cardiovascular product pipeline, 2006
Table 4.42: Merck’s CVD product portfolio, 2005-06
Table 4.43: Merck’s cardiovascular R&D product pipeline, 2006
Table 4.44: Novartis’ CVD product portfolio, 2005-06
Table 4.45: Novartis’ cardiovascular R&D product pipeline, 2006
Table 4.46: Sanofi Aventis’ CVD product portfolio, 2005-06
Table 4.47: Sanofi Aventis’ cardiovascular R&D product pipeline, 2006
Table 4.48: AstraZeneca’s CVD product portfolio, 2005-06
Table 4.49: AstraZeneca’s cardiovascular R&D product pipeline, 2006
Table 4.50: BMS’s CVD product portfolio, 2005-06
Table 4.51: BMS’ cardiovascular R&D product pipeline, 2006
Table 4.52: Daiichi’s CVD product portfolio, 2005-06
Table 4.53: Daichii’s cardiovascular R&D product pipeline, 2006
Table 4.54: Servier’s CVD product portfolio, 2005-06
Table 4.55: GSK’s CVD product portfolio, 2005-06
Table 4.56: GSK’s cardiovascular R&D product pipeline, 2006